JP2015505822A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015505822A5 JP2015505822A5 JP2014543572A JP2014543572A JP2015505822A5 JP 2015505822 A5 JP2015505822 A5 JP 2015505822A5 JP 2014543572 A JP2014543572 A JP 2014543572A JP 2014543572 A JP2014543572 A JP 2014543572A JP 2015505822 A5 JP2015505822 A5 JP 2015505822A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- specific antibody
- heterodimer specific
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161563430P | 2011-11-23 | 2011-11-23 | |
| US61/563,430 | 2011-11-23 | ||
| US201261599221P | 2012-02-15 | 2012-02-15 | |
| US61/599,221 | 2012-02-15 | ||
| PCT/US2012/066345 WO2013078375A2 (en) | 2011-11-23 | 2012-11-21 | Administration of alpha4beta7 hetero-dimer-specific antibody |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017165395A Division JP6564435B2 (ja) | 2011-11-23 | 2017-08-30 | アルファ４ベータ７ヘテロ二量体特異抗体の投与 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015505822A JP2015505822A (ja) | 2015-02-26 |
| JP2015505822A5 true JP2015505822A5 (enExample) | 2016-01-21 |
| JP6203740B2 JP6203740B2 (ja) | 2017-09-27 |
Family
ID=47291275
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014543572A Active JP6203740B2 (ja) | 2011-11-23 | 2012-11-21 | アルファ４ベータ７ヘテロ二量体特異抗体の投与 |
| JP2017165395A Active JP6564435B2 (ja) | 2011-11-23 | 2017-08-30 | アルファ４ベータ７ヘテロ二量体特異抗体の投与 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017165395A Active JP6564435B2 (ja) | 2011-11-23 | 2017-08-30 | アルファ４ベータ７ヘテロ二量体特異抗体の投与 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9914779B2 (enExample) |
| EP (2) | EP3492099A1 (enExample) |
| JP (2) | JP6203740B2 (enExample) |
| AU (1) | AU2012340621B2 (enExample) |
| CA (1) | CA2856866C (enExample) |
| MX (1) | MX366936B (enExample) |
| WO (1) | WO2013078375A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113621027A (zh) | 2014-05-16 | 2021-11-09 | 领导医疗有限公司 | α4β7整联蛋白硫醚肽拮抗剂 |
| EP4031562A4 (en) * | 2019-09-20 | 2023-11-01 | University of Florida Research Foundation, Incorporated | DETECTION OF ANTIBODIES AGAINST RAN PROTEINS FROM SERUM AND TISSUE LYSATES |
| AU2021205415A1 (en) * | 2020-01-10 | 2022-07-21 | Protagonist Therapeutics, Inc. | Methods for treating inflammatory bowel diseases with α4β7 integrin antagonists |
| WO2024249568A1 (en) | 2023-05-30 | 2024-12-05 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
| CN116482345B (zh) * | 2023-06-16 | 2023-09-22 | 军科正源（北京）药物研究有限责任公司 | 用于检测双靶点药物受体占有率的方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010046496A1 (en) | 2000-04-14 | 2001-11-29 | Brettman Lee R. | Method of administering an antibody |
| MY162179A (en) * | 2004-04-01 | 2017-05-31 | Elan Pharm Inc | Steroid sparing agents and methods of using same |
| WO2008115504A2 (en) * | 2007-03-20 | 2008-09-25 | Millennium Pharmaceuticals, Inc. | Nucleic acids encoding humanized immunoglobulin that binds a4b7 integrin |
| SI2279004T1 (sl) * | 2008-05-16 | 2015-05-29 | F. Hoffmann-La Roche Ag | Uporaba biomarkerjev za ocenjevanje zdravljenja gastrointestinalnih vnetnih motenj z antagonisti beta7 integrina |
| CN102388068B (zh) | 2009-03-20 | 2015-05-20 | 安姆根有限公司 | α-4-β-7异二聚体特异性拮抗剂抗体 |
| EP2523688B1 (en) * | 2010-01-15 | 2017-10-11 | Kirin-Amgen, Inc. | Antibody formulation and therapeutic regimens |
-
2012
- 2012-11-21 WO PCT/US2012/066345 patent/WO2013078375A2/en not_active Ceased
- 2012-11-21 JP JP2014543572A patent/JP6203740B2/ja active Active
- 2012-11-21 CA CA2856866A patent/CA2856866C/en active Active
- 2012-11-21 MX MX2014006265A patent/MX366936B/es active IP Right Grant
- 2012-11-21 EP EP18196666.4A patent/EP3492099A1/en not_active Withdrawn
- 2012-11-21 US US14/360,087 patent/US9914779B2/en active Active
- 2012-11-21 EP EP12795715.7A patent/EP2782599B1/en active Active
- 2012-11-21 AU AU2012340621A patent/AU2012340621B2/en active Active
-
2017
- 2017-08-30 JP JP2017165395A patent/JP6564435B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Alsoussi et al. | A potently neutralizing antibody protects mice against SARS-CoV-2 infection | |
| Sureshchandra et al. | Single-cell profiling of T and B cell repertoires following SARS-CoV-2 mRNA vaccine | |
| Schrezenmeier et al. | Immunogenicity of COVID-19 tozinameran vaccination in patients on chronic dialysis | |
| Cabrera-Perez et al. | Alterations in antigen-specific naive CD4 T cell precursors after sepsis impairs their responsiveness to pathogen challenge | |
| Burnett et al. | Immunizations with diverse sarbecovirus receptor-binding domains elicit SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerability | |
| Waickman et al. | Dissecting the heterogeneity of DENV vaccine-elicited cellular immunity using single-cell RNA sequencing and metabolic profiling | |
| Falta et al. | Identification of beryllium-dependent peptides recognized by CD4+ T cells in chronic beryllium disease | |
| Kim et al. | Targeting inducible costimulator expressed on CXCR5+ PD-1+ TH cells suppresses the progression of pemphigus vulgaris | |
| CN117327650A (zh) | 离体bite激活的t细胞 | |
| JP6868655B2 (ja) | Ｃｄ６結合パートナーの使用およびそれに基づく方法 | |
| TW201243328A (en) | Diagnostic and therapeutic uses for B cell maturation antigen | |
| CN116249710A (zh) | 治疗性抗体 | |
| JP2015505822A5 (enExample) | ||
| Hsieh et al. | T cells in multisystem inflammatory syndrome in children (MIS-C) have a predominant CD4+ T helper response to SARS-CoV-2 peptides and numerous virus-specific CD4− CD8− double-negative T cells | |
| Zhang et al. | IL-21–producing effector Tfh cells promote B cell alloimmunity in lymph nodes and kidney allografts | |
| Strongin et al. | Distinct SIV-specific CD8+ T cells in the lymph node exhibit simultaneous effector and stem-like profiles and are associated with limited SIV persistence | |
| CN117534761A (zh) | 一种抗cd28纳米抗体及其制备方法与应用 | |
| Dulovic et al. | Comparative magnitude and persistence of humoral SARS-CoV-2 vaccination responses in the adult population in Germany | |
| Nelson et al. | The inflammaging microenvironment induces dysfunctional rewiring of Tfh cell differentiation | |
| CN102775486B (zh) | 监测肾损伤的新型试剂和试剂盒 | |
| Kato et al. | Early detection of cytomegalovirus-specific cytotoxic T lymphocytes against cytomegalovirus antigenemia in human leukocyte antigen haploidentical hematopoietic stem cell transplantation | |
| Vallejo et al. | Cellular responses to membrane and nucleocapsid viral proteins are also boosted after SARS-CoV-2 spike mRNA vaccination in individuals with either past infection or cross-reactivity | |
| JP2023515265A (ja) | 新規ｔ細胞特異性とその使用 | |
| JP2023515875A (ja) | 抗ｃｄ１２３抗体またはキメラ抗原受容体（ｃａｒ）に結合する抗イディオタイプ抗体、およびそれを使用する方法 | |
| WO2025056144A1 (en) | Methods for monitoring and for assessing the efficacy of treg cell therapies |